Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2025 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
TVRD on Nasdaq
Shares outstanding
9,470,889
Price per share
$4.55
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
2,824,911
Total reported value
$12,111,919
% of total 13F portfolios
0%
Share change
+220,972
Value change
-$18,315,547
Number of holders
64
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Slate Path Capital LP 7.5% $19,257,627 704,118 Slate Path Capital LP 30 Jun 2025
DePinho Ronald A 4.5% $1,939,164 426,190 Ronald A. DePinho 31 Dec 2025
Vifor (International) Ltd 2.2% $4,725,695 205,465 Vifor (International) Ltd. 15 Apr 2025

As of 31 Dec 2025, 64 institutional investors reported holding 2,824,911 shares of Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD). This represents 30% of the company’s total 9,470,889 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD) together control 29% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Slate Path Capital LP 7.4% 704,118 0% 0.04% $3,027,707
VANGUARD GROUP INC 4.5% 424,821 +1.3% 0% $1,826,730
BlackRock, Inc. 4.1% 391,000 +19% 0% $1,681,300
AMERICAN FINANCIAL GROUP INC 2.4% 223,659 0.35% $961,734
GEODE CAPITAL MANAGEMENT, LLC 1.7% 157,133 +6.2% 0% $675,826
STATE STREET CORP 1.2% 115,501 +84% 0% $496,654
RENAISSANCE TECHNOLOGIES LLC 1.1% 104,500 +246% 0% $449,350
SILVERCREST ASSET MANAGEMENT GROUP LLC 1.1% 101,034 +352% 0% $434,446
MORGAN STANLEY 0.89% 84,466 +2131% 0% $363,205
Duncan Williams Asset Management, LLC 0.85% 80,771 0.08% $311,776
Squarepoint Ops LLC 0.55% 51,783 +534% 0% $222,667
NORTHERN TRUST CORP 0.51% 47,882 +13% 0% $205,893
JANE STREET GROUP, LLC 0.5% 47,444 0% $204,010
FARALLON CAPITAL MANAGEMENT LLC 0.46% 43,225 0% 0% $185,868
UBS Group AG 0.38% 35,555 -27% 0% $152,887
GOLDMAN SACHS GROUP INC 0.35% 33,131 +38% 0% $142,463
BANK OF AMERICA CORP /DE/ 0.27% 25,382 +65% 0% $109,142
Quadrature Capital Ltd 0.22% 20,964 0% $90,145
Bank of New York Mellon Corp 0.19% 18,146 +88% 0% $78,027
Russell Investments Group, Ltd. 0.17% 15,966 +1351% 0% $68,654
XTX Topco Ltd 0.14% 12,838 0% $55,203
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.12% 11,802 -23% 0% $50,749
HRT FINANCIAL LP 0.12% 11,050 0% $47,000
TWO SIGMA INVESTMENTS, LP 0.11% 10,492 0% $45,116
Arax Advisory Partners 0.09% 8,400 +277% 0% $36,120

Institutional Holders of Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 2,824,911 $12,111,919 -$18,315,547 $4.30 64
2025 Q3 2,603,814 $101,367,779 +$26,943,937 $38.97 64
2025 Q2 1,922,982 $44,387,703 +$44,380,704 $23.33 48